Filing Flows › Collegium Pharmaceutical (COLL) › How it makes money
How Collegium Pharmaceutical (COLL) makes money
Collegium Pharmaceutical (COLL) made $216M of revenue in the third quarter 2026 (Q3 2026), +3% from a year earlier. Belbuca brought in $57.7M (27%); Jornay PM brought in $51.9M (24%); Xtampza ER brought in $45.8M (21%). Of every dollar of revenue, 58¢ was left as gross profit, 13¢ was left as operating profit, 10¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Belbuca | $57.7M | 26.7% | +0.1% | -0.9% |
| Jornay PM | $51.9M | 24.0% | +13% | +24% |
| Xtampza ER | $45.8M | 21.2% | +2% | -9% |
| Azstarys | $26.5M | 12.3% | +105% | — |
| Nucynta IR | $16.7M | 7.7% | +16% | -48% |
| Nucynta ER | $9.9M | 4.6% | -37% | -57% |
| Nucynta ER AG | $3.9M | 1.8% | +40% | — |
| Symproic | $3.6M | 1.7% | +20% | -10% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $216M | 100.0% |
| Cost of revenue | $90.9M | 42.1% |
| Gross profit | $125M | 58.0% |
| Operating expenses | $96.7M | 44.8% |
| Operating profit | $28.7M | 13.3% |
| Net earnings | $21.8M | 10.1% |
| Operating cash flow | $86.5M | 40.1% |
| Free cash flow | $86.3M | 39.9% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $216M | +3% |
| Q2 2026 | $200M | +6% |
| Q1 2026 | $194M | +9% |
| Q4 2025 | $205M | +13% |
| Q3 2025 | $209M | +31% |
| Q2 2025 | $188M | +29% |
| Q1 2025 | $178M | +23% |
From Collegium Pharmaceutical's 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does Collegium Pharmaceutical make money?
Collegium Pharmaceutical (COLL) made $216M of revenue in the third quarter 2026 (Q3 2026), +3% from a year earlier. Belbuca brought in $57.7M (27%); Jornay PM brought in $51.9M (24%); Xtampza ER brought in $45.8M (21%). Of every dollar of revenue, 58¢ was left as gross profit, 13¢ was left as operating profit, 10¢ was left as net earnings.
What is Collegium Pharmaceutical's biggest business?
Belbuca: $57.7M in the third quarter 2026, 27% of revenue, -0.9% from a year earlier.
What is Collegium Pharmaceutical's profit margin?
Net earnings were $21.8M, 10.1% of revenue, in the third quarter 2026; the operating margin was 13.3%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.